Nocloprost
1
Nocloprost: gastroprotective without systemic adverse effects Schering's novel prostaglandin E2 analogue, nocIoprost [phase II], does not affect gastric acid secretion or cause adverse systemic effects at oral doses found to be gastroprotective against aspirin damage, according to a Polish study. The study indicated that the drug has the unique ability to act locally on the gastric mucosa while only small amounts reach the systemic circulation. Thus, nocloprost is virtually devoid of systemic prostaglandin E2 effects on other organs. No changes in BP, HR, body temperature, or GI symptoms occurred in the 28 patients evaluated. NocIoprost may be useful in combination with NSAIDs to prevent damage to the gastric mucosa; this damage is thought to result from reduced prostaglandin biosynthesis caused by the NSAlDs. The drug may also be useful for treating damaged mucosa in other conditions of reduced prostaglandin synthesis, such as in critically ill patients. Its use may be expanded because it does not increase the intragastric pH, and therefore may reduce the risk of bacterial overgrowth and sepsis. Konturek SJ, Kwiecien N, Obtulowicz W, Maczka J, Hebzda Z, et al. Effects of nocloprost on gastric functions in man. Scandinavian Journal of Gastroenterology 26: 1145-1151, Nov 1991 _ ISSN 0156-170Jj91jI21I-lJlJll7/OS01.INJ/O 0 Alia l.tn'IUItiouI Ltll 7
Transcript of Nocloprost
Nocloprost: gastroprotective without systemic adverse effects
Schering's novel prostaglandin E2 analogue, nocIoprost [phase II], does not affect gastric acid secretion or cause adverse systemic effects at oral doses found to be gastroprotective against aspirin damage, according to a Polish study.
The study indicated that the drug has the unique ability to act locally on the gastric mucosa while only small amounts reach the systemic circulation. Thus, nocloprost is virtually devoid of systemic prostaglandin E2 effects on other organs. No changes in BP, HR, body temperature, or GI symptoms occurred in the 28 patients evaluated.
NocIoprost may be useful in combination with NSAIDs to prevent damage to the gastric mucosa; this damage is thought to result from reduced prostaglandin biosynthesis caused by the NSAlDs. The drug may also be useful for treating damaged mucosa in other conditions of reduced prostaglandin synthesis, such as in critically ill patients. Its use may be expanded because it does not increase the intragastric pH, and therefore may reduce the risk of bacterial overgrowth and sepsis. Konturek SJ, Kwiecien N, Obtulowicz W, Maczka J, Hebzda Z, et al. Effects of nocloprost on gastric functions in man. Scandinavian Journal of Gastroenterology 26: 1145-1151, Nov 1991 _
ISSN 0156-170Jj91jI21I-lJlJll7/OS01.INJ/O 0 Alia l.tn'IUItiouI Ltll
7
